China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Nov 20 (Reuters) -Eli Lilly LLY.N and Hong Kong-listed Laekna 2105.HK will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle, the biotech said on Wednesday.
WHY IT MATTERS
Lilly is aiming to strengthen its position as a leader in the obesity treatment market, which is expected to hit $150 billion in revenue by the next decade. Last year, the company spent about $2 billion to acquire Versanis' drug that acts directly on fat cells, without prompting lean mass loss.
Several other drugmakers including Regeneron REGN.O and Scholar Rock SRRK.O are testing treatments that could help preserve muscle, which is often lost when patients lose weight through lifestyle changes, bariatric surgery or the use of GLP-1 treatments such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO Wegovy.
CONTEXT
The collaboration will accelerate the development of Laekna's experimental drug, LAE102, which belongs to a class of drugs that play a key role in muscle regeneration as well as the breakdown and storage of fat for energy.
Lilly will fund the development of the drug and share its resources and expertise, but Laekna will retain the global rights for the drug and plans to advance the early-stage trial of the drug in China.
Laekna said the drug has shown to increase lean mass and decrease fat mass in lab studies. In combination with a GLP-1 treatment, it could further reduce fat mass and help patients significantly regain the lean mass lost during weight loss.
Reporting by Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
